Abstract
Chimeric Antigen Receptor (CAR) T therapy represents a promising approach to improve outcomes for patients with high-grade gliomas (HGG). Recently, we reported on a phase I trial assessing the local delivery of CAR T cells for HGG. Despite notable clinical benefits to CAR T treatment, clinical responses were highly variable between patients. Here we report that TGFβ levels in the tumor cavity fluid (TCF) decreased following CAR T treatment and that lower TGFβ levels positively correlated with improved patient responses to CAR T therapy. Patients were stratified based on baseline TGFβ levels in the TCF before CAR T therapy. Single-cell RNA sequencing of patient tumor tissues identified significant upregulation of genes associated with angiogenesis and epithelial-to-mesenchymal transition, and IL6 and SLRP pathways in TGFβ high patients, while IL2, chemokine signaling and NK-mediated cytotoxicity pathways were significantly upregulated in TGFβ low patients. Preclinically, we demonstrated that systemic treatment with a TGFβR1 inhibitor markedly improved CAR T efficacy in syngeneic murine glioma models, correlating with changes in the tumor microenvironment (TME) that benefited both endogenous and CAR T cell phenotype and trafficking. Further studies demonstrated that inhibition of the TGFβ pathway in CAR T cells, through either TGFβR1 inhibitor or CRISPR/Cas9 knockout of TGFβR2 (TGFβR2-KO), significantly enhanced CAR T cell expansion and antitumor activity. Collectively, our clinical and preclinical findings strongly indicate that targeting the TGFβ pathway could significantly enhance CAR T therapy for patients with high-grade gliomas.
One Sentence Summary
High TGFβ levels in tumor is linked to resistance to CAR T therapy in GBM patients supporting targeting this pathway to enhance CAR T therapy for GBM.
Full Text Availability
The license terms selected by the author(s) for this preprint version do not permit archiving in PMC. The full text is available from the preprint server.
